ulcerative colitis

News

UEGW delegates hear of strides forward in IBD treatment

Trials of Lilly's Omvoh, Gilead's emvistegrast, Takeda's Entyvio, AbbVie's ABBV-466, and Sanofi/Teva's duvakitug are highlights of UEGW.

News

New biotech Avere plots listing via NextCure merger

New biotech Avere has taken a fast-track to becoming a listed company by merging with NextCure and raising $305m for an oral IL-23 drug for psoriasis.

News

MSD's TL1A drug tulisokibart delivers in pivotal IBD trial

MSD's tulisokibart has become the first anti-TL1A antibody to help patients with ulcerative colitis achieve clinical remission in a phase 3 trial.

News

Abivax slides on phase 3 data in ulcerative colitis

Shares in Abivax have tumbled after it announced phase 3 data with ulcerative colitis drug obefazimod that included several cases of cancer.

News

MSD taps Quotient for IBD drug targets in $2.2bn deal

MSD is paying $20m upfront to activate an alliance with Flagship's Quotient Therapeutics to find new targets in inflammatory bowel disease.

News

Earendil raises $787m as lead TL1A antibody starts phase 2

Earendil has raised an impressive $787m in financing for its AI-powered drug platform, attracting yet more buy-in from Sanofi.

UEGW delegates hear of strides forward in IBD treatment

New biotech Avere plots listing via NextCure merger

MSD's TL1A drug tulisokibart delivers in pivotal IBD trial

Abivax slides on phase 3 data in ulcerative colitis

MSD taps Quotient for IBD drug targets in $2.2bn deal

Earendil raises $787m as lead TL1A antibody starts phase 2

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

ulcerative colitis

Editor's Picks